News
- Experimental glioma model reveals novel approach for immunotherapy in glioblastoma patients
- Michael Platten among the most highly cited researchers worldwide
- Lukas Bunse receives award for the development of cellular therapies
- Together against glioma - DKFZ part of new CRC
- German Cancer Award 2019 goes to Michael Platten
- Prof. Michael Platten and The Platten Lab are on Twitter
Experimental glioma model reveals novel approach for immunotherapy in glioblastoma patients
© Fotolia
Malignant brain tumors, such as glioblastomas are frequently resistant to immunotherapies. Scientists from Prof. Dr. Michael Platten's lab at the German Cancer Research Center and Mannheim University Hospital were able to identifiy a mechanism of restistance to immune checkpoint blockade in a mouse model of glioma. (Katrin Aslan, et al. Nature Communications, 2020)
to press release (in German only)
Michael Platten among the most highly cited researchers worldwide
© dkfz.de
Nine researchers at dkfz are among the world's most influential researchers of the past decade, demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations for field and year. Michael Platten is included in this ranking of "Highly Cited Researchers" in the "cross-field" category.
to press release (in German only)
Lukas Bunse receives award for the development of cellular therapies
© Uwe Anspach/DKFZ
Lukas Bunse from the German Cancer Research Center in Heidelberg and the University Hospital Mannheim receives this year's Swiss Bridge award. Bunse shares the award with a Swiss scientist. Both of them receive 250,000 Swiss francs for the implementation of their research projects.
to press release (in German only)
Together against glioma - DKFZ part of new CRC
© P. Kickingereder / University Hospital Heidelberg
With Collaborative Research Centres (CRCs), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) allows researchers to tackle innovative, challenging, complex and long-term research undertakings through the coordination and concentration of individuals and resources within the applicant universities. The new CRC 1389 "Understanding and targeting resistance in glioblastoma – UNITEGLIOBLASTOMA" aims to develop concepts to predict and monitor treatment response and failure, and ultimately, to invent novel therapies for glioblastoma patients.
to press release (in German only)
German Cancer Award 2019 goes to Michael Platten
Prof. Dieter Saur (Munich), Prof. Michael Platten (Mannheim/Heidelberg), Prof. Ugur Sahin (Mainz) and Prof. Roland Rad (Munich)
© EMBL Photolab
Prof. Dr. Michael Platten has been awarded the German Cancer Award 2019, one of the most prestigious distinctions in cancer medicine in Germany. Prof. Platten receives the award in the category Clinical Research for his work on immunotherapies for glioma, in particular for the discovery and development of a vaccine against IDH1 (isocitrate dehydrogenase 1), a common mutation found in low-grade gliomas.
to press release (in German only)
Prof. Michael Platten and The Platten Lab are on Twitter
For more up to date information and news, we highly recommend following us on Twitter!
Follow Prof. Michael Platten on Twitter: @platten_michael
Follow The Platten Lab on Twitter: @Platten_lab